Six million euros for optimal use of antithrombotic medication during final stage of life

13 June 2022• PRESSRELEASE

Despite the fact that antithrombotic medications are associated with high rates of bleeding in cancer patients during the last phase of their lives, it is rarely deprescribed. A European consortium, led by the Leiden University Medical Centre (LUMC), has been awarded a Horizon Europe grant of 6 million euros to create an online app that facilitates the shared decision making between doctors and patients regarding the discontinuation of their anti-thrombotic medicines.

Erik Klok, Professor of Medicine at the LUMC (the Netherlands) and Simon Noble, Marie Curie Professor in Supportive and Palliative Medicine at Cardiff University (Wales, UK) initiated the SERENITY project. Many patients with cancer receive antithrombotic medication. These drugs reduce the ability of the blood to clot, thereby reducing the risk of thrombosis. They are often continued until death, despite side effects such as bleeding, and the associated reduced quality of life. "Only rarely are these medications discontinued during the last phase of life," say Klok and Noble. "This is due to the lack of scientific evidence, but also because death and dying are often not discussed sufficiently by the treating physician."

Stop or continue?

Klok, Noble and their colleagues hope to encourage this discussion with a dedicated online app. This app uses questions to start the conversation between physician and patient and assesses the patient's individual risk of bleeding and thrombosis. "We want to tailor the app as much as possible to the individual patient. We take into account factors such as gender, tumour type and past thrombosis / bleeding history. The questions in the app will be adjusted accordingly." Klok emphasises that the app does not indicate whether the patient should stop taking medication. "The app does not give any advice, but makes discontinuing medication negotiable. The final decision lies with the patient, giving them more control over their own disease process. Most importantly, it helps them to consider the evidence within the context of their own personal preferences and values." 

SERENITY

The LUMC and Cardiff University are collaborating with 14 institutions across Europe in order to develop an app with the broadest possible relevance. The first two years of the SERENITY project will be dedicated to epidemiological studies, qualitative research, consensus building and app development. A great deal of attention will be paid to the perspectives of doctors and patients. "After that, we will test the app in practice. We will compare the results of patients who have used the app with those who have not. Our expectation is that the app will lead to the appropriate use of antithrombotic medication, prevention of bleeding complications and significant cost savings, in addition to an improvement in the quality of life and treatment satisfaction of patients, their carers and the healthcare professionals involved", says Noble.

The grant is part of the European Commission's Horizon Europe programme.